Scholarlink

<p>Targeted therapies are indispensable in today’s cancer treatment and represent a&#xa0;constantly evolving field by creating more individual treatment strategies and reducing chemotherapy-associated toxicities. At the SABCS 2024 (San Antonio Breast Cancer Symposium), several studies were presented, offering exciting prospects for future therapeutic developments in the area of targeted therapies for breast cancer. Particularly noteworthy is the new maintenance therapy with palbociclib/endocrine therapy/trastuzumab/pertuzumab in HER2-positive metastatic breast cancer, which has already been included in clinical guidelines.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Post—SABCS: update on targeted therapies in breast cancer

  • 期刊论文

  • 发表日期：

    2025年9月1日

查看全文
  • Lea Korber,
  • Kathrin Strasser-Weippl

摘要

Targeted therapies are indispensable in today’s cancer treatment and represent a constantly evolving field by creating more individual treatment strategies and reducing chemotherapy-associated toxicities. At the SABCS 2024 (San Antonio Breast Cancer Symposium), several studies were presented, offering exciting prospects for future therapeutic developments in the area of targeted therapies for breast cancer. Particularly noteworthy is the new maintenance therapy with palbociclib/endocrine therapy/trastuzumab/pertuzumab in HER2-positive metastatic breast cancer, which has already been included in clinical guidelines.